Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer
- 844 Downloads
Previous studies have reported significantly worse outcomes in younger women with breast cancer. The cut-off for young age differed between studies and it is unclear whether the survival-age relationship is a linear function across age in premenopausal women. We analyzed data on 9,885 breast cancer patients aged ≤50 years who entered the Korean Breast Cancer Society Registration Program between 1992 and 2001. Overall survival data were compared among age groups. The median follow-up duration was 74.4 months. Of all patients, 351 were aged <30 years (Group I), 1,092 were aged 30–34 years (Group II), 2,087 were aged 35–39 years (Group III), and 6,354 were aged 40–50 years (Group IV). In univariate and multivariate analyses, Group I patients showed a worse outcome than Group II patients, and Group II patients showed a worse outcome than Group III patients. Interestingly, the survival rates of Group III and Group IV patients did not differ significantly. This survival trend according to age group was not found in the subgroup of patients with hormone receptor-negative tumors. In patients aged <35 years, the risk of death rose by 5% for every 1-year reduction in age, whereas there was no significant change in death risk with age in patients aged 35–50 years. We show that risk of death from breast cancer increases sharply in women younger than 35 years. This suggests that age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer.
KeywordsBreast cancer Young age Prognosis Survival Premenopausal
The Korean Breast Cancer Society thanks the following members who participated in this national study: S.H. Ahn, J.W. Bae, Y.T. Bae, J.W. Baek, J.G. Bong, K.H. Cha, E.S. Chang, I.T. Chang, S.S. Chang, J.W. Cho, S.H. Cho, Y.U. Cho, J.W. Choi, K.J. Choi, M.S. Choi, S.I. Choi, S.Y. Choi, G.S. Goo, S.H. Han, W. Han, S.J. Hong, J.Y. Hwang, T.I. Hyun, Y.J. Jegal, M.G. Im, Y.G. Joh, S.Y. Jun, B.W. Jung, J. Jung, J.H. Jung, K.H. Jung, P.J. Jung, S.H. Jung, S.S. Jung, Y.H. Jung, Y.S. Jung, D.H. Kang, H.J. Kang, Y.I. Kang, Y.J. Kang, J.H. Keum, D.Y. Kim, H.J. Kim, J.G. Kim, J.H. Kim, J.S. Kim, J.S. Kim, K.C. Kim, S.C. Kim, S.H. Kim, S.I. Kim, S.J. Kim, S.W. Kim, S.W. Kim, S.Y. Kim, S.Y. Kim, Y.S. Kim, B.K. Ko, S.S. Ko, S.H. Koh, B.H. Koo, J.Y. Koo, B.S. Kwak, C.H. Lee, C.H. Lee, D.H. Lee, D.S. Lee, E.S. Lee, G.S. Lee, H.D. Lee, H.S. Lee, J.C. Lee, J.H. Lee, J.K. Lee, J.S. Lee, J.Y. Lee, K.M. Lee, K.P. Lee, K.S. Lee, K.Y. Lee, M.H. Lee, R.A. Lee, S.C. Lee, S.J. Lee, S.K. Lee, W. Lee, Y.H. Lee, J.W. Leu, C.H. Lim, C.W. Lim, B.I. Moon, Y.S. Nam, S.J. Nam, D.Y. Noh, W.C. Noh, S.J. Oh, S.S. Oh, W.K. Pae, I.W. Paik, N.S. Paik, B.G. Park, B.W. Park, C.H. Park, H.B. Park, H.Y. Park, J.H. Park, K.H. Park, S.J. Park, S.T. Park, S.W. Park, W.C. Park, Y.K. Park, Y.K. Park, H.S. Seo, K.H. Seo, Y.J. Seo, Y.S. Sin, B.H. Son, G.S. Son, B.J. Song, K.H. Song, Y.J. Song, Y.J. Suh, J.M. Won, D.H. Woo, D.H. Yang, J.H. Yang, K.Y. Yoo, S.Y. Yoo, H.S. Yoon, J.H. Yoon, and S.O. Yoon.
- 2.Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360–2368. doi: 10.1200/JCO.2006.10.3754 CrossRefPubMedGoogle Scholar
- 9.Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869–1874. doi: 10.1016/S0140-6736(00)02292-3 CrossRefPubMedGoogle Scholar
- 10.Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, Viale G, Pruneri G, Veronesi P, Luini A, Intra M, Cardillo A, Torrisi R, Rocca A, Goldhirsch A (2006) Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17:1497–1503. doi: 10.1093/annonc/mdl145 CrossRefPubMedGoogle Scholar
- 12.International Breast Cancer Study Group (1996) Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 14:1885–1894Google Scholar
- 15.Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, Catalano G, Galimberti V, Nole F, Martinelli G, Goldhirsch A (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273–279. doi: 10.1093/annonc/mdf039 CrossRefPubMedGoogle Scholar
- 16.Dai H, van’t Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65:4059–4066. doi: 10.1158/0008-5472.CAN-04-3953 CrossRefPubMedGoogle Scholar
- 17.Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826. doi: 10.1056/NEJMoa041588 CrossRefPubMedGoogle Scholar
- 18.Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330. doi: 10.1200/JCO.2007.14.2471 CrossRefPubMedGoogle Scholar